Search hospitals > Illinois > Canton
Illinois CancerCare-Canton
Claim this profileCanton, Illinois 61520
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Non-Small Cell Lung Cancer
384 reported clinical trials
2 medical researchers
Summary
Illinois CancerCare-Canton is a medical facility located in Canton, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Illinois CancerCare-Canton is involved with conducting 384 clinical trials across 476 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Bryan A. FallerCrossroads Cancer Center2 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
226 reported clinical trials
291 drugs studied
James L. WadeDecatur Memorial Hospital3 years of reported clinical research
Studies Recurrence
Studies Breast Cancer
11 reported clinical trials
20 drugs studied
Clinical Trials running at Illinois CancerCare-Canton
Breast Cancer
Prostate Cancer
Cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Gastric Cancer
Lung Cancer
Gastroesophageal Junction Adenocarcinoma
Esophageal Cancer
Squamous Cell Carcinoma
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Illinois CancerCare-Canton?
Illinois CancerCare-Canton is a medical facility located in Canton, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Illinois CancerCare-Canton is involved with conducting 384 clinical trials across 476 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.
Where is Illinois CancerCare-Canton located?
**Illinois CancerCare - Canton Office**
- **Address:** 180 S. Main St, Suite 2E, Canton, IL 61520
- **Open Days:** Wednesdays and Thursdays
- **Attending Physician:** Dr. Paul A. S. Fishkin
Who should I call to ask about financial aid or insurance network?
Illinois CancerCare-Canton offers financial assistance and insurance guidance. Contact them at (309) 243-3000, (866) 662-6564, or via their website. Organizations like the Partnership for Prescription Assistance, Patient Advocate Foundation Co-Pay Relief Program, and Good Days provide co-pay relief for cancer treatments. Graham Health System and OSF Healthcare, including Illinois CancerCare, offer billing and financial assistance; contact Graham Health System at 309-649-6818 for hospital bills and 309-647-0201 for medical group bills.
What insurance does Illinois CancerCare-Canton accept?
Illinois CancerCare-Canton accepts a wide range of insurance plans, including but not limited to Medicare, Aetna (HMO, PPO, POS), BCBS of Illinois (PPO, POS, EPO, Classic Blue HMO, HMOI, Blue Advantage HMO), Beech Street PPO, Cigna/Great West Healthcare (HMO, PPO, POS, Open Access), and United Health Care. They also accept Coventry/First Health/Personal Care, Humana (HMO, PPO, Choice POS, Choice Care Network), Multiplan, PHCS (PHCS, Savility PPO), and more. Patients are advised to confirm their physician's participation in their insurance plan and notify the office of any necessary pre-certification.
What awards or recognition has Illinois CancerCare-Canton received?
Illinois CancerCare-Canton, located in Canton, Illinois, is nationally recognized as a top community research center by the American Society of Clinical Oncology. It has earned awards for advancing new cancer treatments through clinical trials by the Alliance for Clinical Trials in Oncology. Additionally, it is certified by the Quality Oncology Practice Initiative (QOPI®) for meeting the highest standards in outpatient hematology-oncology practices.